TUM
A fragment of type IV collagen α3 chain generated by matrix metalloproteinase activity, enabling non-invasive monitoring of basement membrane remodeling and angiogenic activity in pathological conditions.
Key features and values
- Quantifies tumstatin, a matrikine derived from type IV collagen α3 chain.
- Reflects basement membrane remodeling associated with pathological angiogenesis.
- Provides a non-invasive measure of extracellular matrix turnover.
- Supports monitoring of disease progression and response to therapies targeting angiogenesis.
- Applicable in research on diseases characterized by abnormal angiogenesis, such as cancer and fibrotic disorders.
- Facilitates evaluation of interventions aimed at modulating basement membrane integrity.
- Complements other biomarkers for a comprehensive assessment of extracellular matrix dynamics.
Description
The TUM biomarker assay measures specific fragments of type IV collagen α3 chain, known as tumstatin, generated by matrix metalloproteinase activity. This non-invasive assay provides insights into basement membrane remodeling and angiogenic activity in pathological conditions. By quantifying tumstatin levels, the TUM assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of diseases characterized by abnormal angiogenesis and extracellular matrix turnover. It serves as a valuable tool in research settings for assessing the dynamics of basement membrane integrity.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
